{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:22:16Z","timestamp":1787840536377,"version":"build-2784847793"},"reference-count":10,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","license":[{"start":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T00:00:00Z","timestamp":1730851200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:title>Abstract:<\/jats:title>\n                  <jats:sec>\n                    <jats:title>PURPOSE:<\/jats:title>\n                    <jats:p>The purpose of the study was to study the efficacy of oral cyclophosphamide monotherapy in advanced resistant ocular cicatricial pemphigoid (OCP).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>MATERIALS AND METHODS:<\/jats:title>\n                    <jats:p>This retrospective case series examines patients diagnosed with advanced resistant OCP at a uveitis tertiary care center who were treated with oral cyclophosphamide therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>\n                      Seventeen patients were included in this study. The average age of the participants was 74.3 \u00b1 10.3 years, ranging from 60 to 99 years. The gender distribution was 8 females to 9 males. Oral cyclophosphamide-induced remission in 7 patients (41.1%) and was prematurely discontinued in 10 patients (58.9%), with 7 (63.7%) citing ineffectiveness and 3 (36.3%) experiencing side effects as reasons for discontinuation. The average therapy dose of cyclophosphamide administered was 116.1 \u00b1 47.5 mg. The average duration required for the induction of remission was 150 \u00b1 128 days. The overall therapy duration averaged 306 \u00b1 189 days. Conducting univariate logistic regression with generalized estimating equations (GEEs) on variables did not reveal statistically significant differences between the two groups (responsive and nonresponsive to oral cyclophosphamide therapy), except for the maximum dose of oral cyclophosphamide therapy (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      = 0.007).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION:<\/jats:title>\n                    <jats:p>The prognosis of advanced OCP in patients is unlikely to be altered by the stepladder approach and step-up strategy. While oral cyclophosphamide can be efficacious for remission induction in resistant and aggressive OCP cases, a step-down strategy employing less potent agents with safer side effect profiles should be contemplated for subsequent treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/tjo.tjo-d-24-00057","type":"journal-article","created":{"date-parts":[[2024,11,6]],"date-time":"2024-11-06T08:00:10Z","timestamp":1730880010000},"page":"290-296","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Oral cyclophosphamide monotherapy in advanced resistant ocular cicatricial pemphigoid"],"prefix":"10.4103","volume":"15","author":[{"given":"Arash","family":"Maleki","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, University of Florida, Gainesville, FL, USA"},{"name":"The Ocular Immunology and Uveitis Foundation, Waltham, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Richey","sequence":"additional","affiliation":[{"name":"The Ocular Immunology and Uveitis Foundation, Waltham, MA, USA"},{"name":"Massachusetts Eye Research and Surgery Institution, Waltham, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hasan","family":"Bashir","sequence":"additional","affiliation":[{"name":"The Ocular Immunology and Uveitis Foundation, Waltham, MA, USA"},{"name":"Massachusetts Eye Research and Surgery Institution, Waltham, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soheila","family":"Asgari","sequence":"additional","affiliation":[{"name":"The Ocular Immunology and Uveitis Foundation, Waltham, MA, USA"},{"name":"Noor Ophthalmology Research Center, Noor Eye Hospital, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tate","family":"Valerio","sequence":"additional","affiliation":[{"name":"The Ocular Immunology and Uveitis Foundation, Waltham, MA, USA"},{"name":"Massachusetts Eye Research and Surgery Institution, Waltham, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmin","family":"Massoudi","sequence":"additional","affiliation":[{"name":"The Ocular Immunology and Uveitis Foundation, Waltham, MA, USA"},{"name":"Massachusetts Eye Research and Surgery Institution, Waltham, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Dolinko","sequence":"additional","affiliation":[{"name":"The Ocular Immunology and Uveitis Foundation, Waltham, MA, USA"},{"name":"Massachusetts Eye Research and Surgery Institution, Waltham, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter Y.","family":"Chang","sequence":"additional","affiliation":[{"name":"The Ocular Immunology and Uveitis Foundation, Waltham, MA, USA"},{"name":"Massachusetts Eye Research and Surgery Institution, Waltham, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Stephen","family":"Foster","sequence":"additional","affiliation":[{"name":"The Ocular Immunology and Uveitis Foundation, Waltham, MA, USA"},{"name":"Massachusetts Eye Research and Surgery Institution, Waltham, MA, USA"},{"name":"Department of Ophthalmology, Harvard Medical School, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen D.","family":"Anesi","sequence":"additional","affiliation":[{"name":"The Ocular Immunology and Uveitis Foundation, Waltham, MA, USA"},{"name":"Massachusetts Eye Research and Surgery Institution, Waltham, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,11,6]]},"reference":[{"key":"R1-20250618","first-page":"3379","article-title":"Ocular cicatricial pemphigoid (review)","volume":"20","author":"Branisteanu","year":"2020","journal-title":"Exp Ther Med"},{"key":"R2-20250618","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.2147\/OPTH.S40319","article-title":"Ocular cicatricial pemphigoid masquerading as chronic conjunctivitis:A case report","volume":"6","author":"Dacosta","year":"2012","journal-title":"Clin Ophthalmol"},{"key":"R3-20250618","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.ophtha.2007.04.027","article-title":"Immunosuppressive therapy for ocular mucous membrane pemphigoid strategies and outcomes","volume":"115","author":"Saw","year":"2008","journal-title":"Ophthalmology"},{"key":"R4-20250618","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/j.ophtha.2005.01.039","article-title":"Evaluation of mucous membrane pemphigoid with ocular involvement in young patients","volume":"112","author":"Rauz","year":"2005","journal-title":"Ophthalmology"},{"key":"R5-20250618","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0161-6420(01)00863-6","article-title":"The effect of treatment and its related side effects in patients with severe ocular cicatricial pemphigoid","volume":"109","author":"Miserocchi","year":"2002","journal-title":"Ophthalmology"},{"key":"R6-20250618","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2165\/00128071-200506020-00004","article-title":"Cicatricial pemphigoid (mucous membrane pemphigoid):Current and emerging therapeutic approaches","volume":"6","author":"Sacher","year":"2005","journal-title":"Am J Clin Dermatol"},{"key":"R7-20250618","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.clim.2003.11.002","article-title":"A nonrandomized comparison of the clinical outcome of ocular involvement in patients with mucous membrane (cicatricial) pemphigoid between conventional immunosuppressive and intravenous immunoglobulin therapies","volume":"111","author":"Letko","year":"2004","journal-title":"Clin Immunol"},{"key":"R8-20250618","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1136\/bjo.79.3.264","article-title":"Role of cyclophosphamide and high dose steroid in ocular cicatricial pemphigoid","volume":"79","author":"Elder","year":"1995","journal-title":"Br J Ophthalmol"},{"key":"R9-20250618","first-page":"527","article-title":"Cicatricial pemphigoid","volume":"84","author":"Foster","year":"1986","journal-title":"Trans Am Ophthalmol Soc"},{"key":"R10-20250618","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1016\/j.ophtha.2008.08.002","article-title":"Treatment of ocular mucous membrane pemphigoid with immunosuppressive drug therapy","volume":"115","author":"Thorne","year":"2008","journal-title":"Ophthalmology"}],"container-title":["Taiwan Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/tjo.TJO-D-24-00057","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:24:38Z","timestamp":1787837078000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/tjo.TJO-D-24-00057"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,6]]},"references-count":10,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/tjo.tjo-d-24-00057","relation":{},"ISSN":["2211-5056","2211-5072"],"issn-type":[{"value":"2211-5056","type":"print"},{"value":"2211-5072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,6]]},"assertion":[{"value":"2024-05-14","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-28","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}